Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

Respiratory Medicine

Volumn 115, Issue , 2016, Pages 72-77

  Crommelin, Heleen A ^a   Van Der Burg, Leone M ^a,b   Vorselaars, Adriane D M ^a   Drent, Marjolein ^a,c   Van Moorsel, Coline H M ^a,d   Rijkers, Ger T ^a,b   Deneer, Vera H M ^a   Grutters, Jan C ^a,d  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b University College Roosevelt   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adalimumab; Anti TNF ; Infliximab; Sarcoidosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL MARKER; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLERGIC REACTION; ANTIBODY PRODUCTION; ARTICLE; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CENTER; HUMAN; HYPERCALCEMIA; LUNG DISEASE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NETHERLANDS; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS; UVEITIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EPIDEMIOLOGY; METABOLISM; TREATMENT OUTCOME; VITAL CAPACITY;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; NETHERLANDS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VITAL CAPACITY;

EID: 84966708387     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.04.011     Document Type: Article

References (44)

1. D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.Y. Brillet, and J. Muller-Quernheim Sarcoidosis Lancet 383 2013 1155 1167
2. J.C. Grutters, and J.M. van den Bosch Corticosteroid treatment in sarcoidosis Eur. Respir. J. 28 2006 627 636
3. N.S. Paramothayan, T.J. Lasserson, and P.W. Jones Corticosteroids for pulmonary sarcoidosis Cochrane Database Syst. Rev. 2 2005 CD001114
4. A.D. Vorselaars, C.H. van Moorsel, V.H. Deneer, and J.C. Grutters Current therapy in sarcoidosis, the role of existing drugs and future medicine Inflamm. Allergy Drug Targets 12 2013 369 377
5. R.P. Baughman, D.B. Winget, and E.E. Lower Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial Sarcoidosis Vasc. Diffus. Lung Dis. 17 2000 60 66
6. E.E. Lower, and R.P. Baughman Prolonged use of methotrexate for sarcoidosis Arch. Intern. Med. 155 1995 846 851
7. J.P. Cremers, M. Drent, A. Bast, H. Shigemitsu, R.P. Baughman, D. Valeyre, and et al. Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide Curr. Opin. Pulm. Med. 19 2013 545 561
8. A.D. Vorselaars, W.A. Wuyts, V.M. Vorselaars, P. Zanen, V.H. Deneer, M. Veltkamp, and et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis Chest 144 2013 805 812
9. M.A. Judson The treatment of pulmonary sarcoidosis Respir. Med. 106 2012 1351 1361
10. R.P. Baughman, E.E. Lower, and M. Drent Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them Sarcoidosis Vasc. Diffus. Lung Dis. 25 2008 76 89
11. M.W. Ziegenhagen, U.K. Benner, G. Zissel, P. Zabel, M. Schlaak, and J. Muller-Quernheim Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers Am. J. Respir. Crit. Care Med. 156 1997 1586 1592
12. A.S. Morgenthau, and M.C. Iannuzzi Recent advances in sarcoidosis Chest 139 2011 174 182
13. R.P. Baughman, M. Drent, M. Kavuru, M.A. Judson, U. Costabel, R. du Bois, and et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am. J. Respir. Crit. Care Med. 174 2006 795 802
14. K.E. Hostettler, U. Studler, M. Tamm, and M.H. Brutsche Long-term treatment with infliximab in patients with sarcoidosis Respiration 83 2012 218 224
15. H.N.A.J. van Rijswijk, A.D.M. Vorselaars, H.T.J. Ruven, R.G.M. Keijsers, P. Zanen, I.H.E. Korenromp, and et al. Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment Expert Opin. Orphan Drugs 1 2013 437 443
16. A.D. Vorselaars, H.A. Crommelin, V.H. Deneer, B. Meek, A.M. Claessen, R.G. Keijsers, and et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis Eur. Respir. J. 46 2015 175 185
17. M. Drent, J.P. Cremers, T.L. Jansen, and R.P. Baughman Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis Sarcoidosis Vasc. Diffus. Lung Dis. 31 2014 91 107
18. J.F. Colombel, B.G. Feagan, W.J. Sandborn, G. Van Assche, and A.M. Robinson Therapeutic drug monitoring of biologics for inflammatory bowel disease Inflamm. Bowel Dis. 18 2012 349 358
19. I. Ordas, B.G. Feagan, and W.J. Sandborn Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease Clin. Gastroenterol. Hepatol. 10 2012 1079 1087
20. C. Steenholdt, M. Svenson, K. Bendtzen, O.O. Thomsen, J. Brynskov, and M.A. Ainsworth Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 34 2011 51 58
21. K.S. Nanda, A.S. Cheifetz, and A.C. Moss Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis Am. J. Gastroenterol. 108 2013 40 47
22. N.J. Sweiss, I. Noth, M. Mirsaeidi, W. Zhang, E.T. Naureckas, D.K. Hogarth, and et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis Sarcoidosis Vasc. Diffus. Lung Dis. 31 2014 46 54
23. N. Milman, N. Graudal, A. Loft, J. Mortensen, J. Larsen, and B. Baslund Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET Clin. Respir. J. 6 2012 238 247
24. R.J. Erckens, R.L. Mostard, P.A. Wijnen, J.S. Schouten, and M. Drent Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis Graefes Arch. Clin. Exp. Ophthalmol. 250 2012 713 720
25. R.J. Pariser, J. Paul, S. Hirano, C. Torosky, and M. Smith A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis J. Am. Acad. Dermatol. 68 2013 765 773
26. P.A. Minnis, M. Poland, M.P. Keane, and S.C. Donnelly Adalimumab for refractory pulmonary sarcoidosis Ir. J. Med. Sci. 2015 10.1007/s11845-015-1363-9
27. Statement on sarcoidosis. joint statement of the american thoracic society (ATS), the european respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999 Am. J. Respir. Crit. Care Med. 160 1999 736 755
28. J.J. Swigris, K.K. Brown, J. Behr, R.M. du Bois, T.E. King, G. Raghu, and et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF Respir. Med. 104 2010 296 304
29. S. Miyoshi, H. Hamada, T. Kadowaki, N. Hamaguchi, R. Ito, K. Irifune, and et al. Comparative evaluation of serum markers in pulmonary sarcoidosis Chest 137 2010 1391 1397
30. N. Keicho, K. Kitamura, F. Takaku, and H. Yotsumoto Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis Chest 98 1990 1125 1129
31. S. Rothkrantz-Kos, M.P. van Dieijen-Visser, P.G. Mulder, and M. Drent Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis Clin. Chem. 49 2003 1510 1517
32. G.J. Wolbink, M. Vis, W. Lems, A.E. Voskuyl, E. de Groot, M.T. Nurmohamed, and et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum. 54 2006 711 715
33. R.P. Baughman Tumor necrosis factor inhibition in treating sarcoidosis: the American experience Rev. Port. Pneumonol. 13 2007 S47 S50
34. R.P. Baughman, E.E. Lower, and A.H. Kaufman Ocular sarcoidosis Semin. Respir. Crit. Care. Med. 31 2010 452 462
35. A.D. Vorselaars, C.H. van Moorsel, P. Zanen, H.J. Ruven, A.M. Claessen, H. van Velzen-Blad, and et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy Respir. Med. 109 2015 279 285
36. M.A. Judson, R.P. Baughman, U. Costabel, M. Drent, K.F. Gibson, G. Raghu, and et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis Eur. Respir. J. 44 2014 1296 1307
37. J.P. Utz, A.H. Limper, S. Kalra, U. Specks, J.P. Scott, Z. Vuk-Pavlovic, and et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis Chest 124 2003 177 185
38. R.L. Mostard, S. Voo, M.J. van Kroonenburgh, J.A. Verschakelen, P.A. Wijnen, P.J. Nelemans, and et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis Respir. Med. 105 2011 1917 1924
39. C.L. Krieckaert, M.T. Nurmohamed, and G.J. Wolbink Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner Ann. Rheum. Dis. 71 2012 1914 1915
40. M.F. Pouw, C.L. Krieckaert, M.T. Nurmohamed, D. van der Kleij, L. Aarden, T. Rispens, and et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve Ann. Rheum. Dis. 74 2015 513 518
41. A. Verwoerd, A.D. Vorselaars, C.H. van Moorsel, W.J. Bos, H. van Velzen-Blad, and J.C. Grutters Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency Eur. Respir. J. 46 2015 277 280
42. L. Riancho-Zarrabeitia, V. Calvo-Rio, R. Blanco, M. Mesquida, A.M. Adan, J.M. Herreras, and et al. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients Semin. Arthritis Rheum. 45 2015 361 368
43. C.F. Amarante, L.M. Acedo, F.M. Rabay, E. Campos Bdo, M.L. Lira, and S.H. Mandelbaum Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab An. Bras. Dermatol. 90 2015 121 124
44. W.J. Sandborn, P. Rutgeerts, R. Enns, S.B. Hanauer, J.F. Colombel, R. Panaccione, and et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann. Intern. Med. 146 2007 829 838